We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > APl

News List

Drug combination an alternative leukaemia treatment to chemotherapy EuropeanPharmaceuticalReview
November 15, 2021
A Phase III clinical trial has found that the combination of all-trans retinoic acid and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukaemia (APL).
Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV Formulations prnasia
May 14, 2021
Australian pharmaceutical group Phebra congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference.
Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia pharmaceutical-business-review
December 09, 2020
Syros Pharmaceuticals announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).